---
title: Secondgeneration vaccines development
videoId: cwpGBCjpJiU
---

From: [[artedeinvertir]] <br/> 

[[Bill Gates vaccine investment strategy|Bill Gates]], one of the world's wealthiest individuals, appears to be preparing for a new crisis similar to past events, evidenced by his significant investments in companies that produce vaccines <a class="yt-timestamp" data-t="00:00:05">[00:00:05]</a>. This represents a radical shift in his [[bill_gates_vaccine_investment_strategy|investment strategy]] <a class="yt-timestamp" data-t="00:00:22">[00:00:22]</a>, with his movements and statements closely followed by investors globally due to his often accurate vision for the future of the economy <a class="yt-timestamp" data-t="00:01:24">[00:01:24]</a>.

## Bill Gates' Investment Focus
Bill Gates' investment portfolio, recently made public, shows a concentrated shift, with 70% of his investments now in just three stocks involved in vaccine production <a class="yt-timestamp" data-t="00:01:46">[00:01:46]</a>. This new [[bill_gates_vaccine_investment_strategy|investment strategy]] is implemented primarily through the portfolio of the Bill and Melinda Gates Foundation <a class="yt-timestamp" data-t="00:02:43">[00:02:43]</a>. The three primary stocks in his portfolio, BioNTech, CureVac, and Vir Biotech, are leading the development of what are known as "second-generation vaccines" <a class="yt-timestamp" data-t="00:02:57">[00:02:57]</a>. These are anticipated to be much more sophisticated and effective against current global health challenges <a class="yt-timestamp" data-t="00:03:10">[00:03:10]</a>.

## Necessity for Second-Generation Vaccines
In an interview with CNN, Bill Gates highlighted concerns regarding the insufficient provision of quality vaccines to the poorest countries by wealthier nations <a class="yt-timestamp" data-t="00:03:30">[00:03:30]</a>. He warned that variants would continue to spread back to richer countries if the problem wasn't tackled quickly enough <a class="yt-timestamp" data-t="00:03:41">[00:03:41]</a>. This situation, according to Gates, necessitates the development of these second-generation vaccines <a class="yt-timestamp" data-t="00:03:47">[00:03:47]</a>. He believes a return to normalcy will only occur with the advent of this next generation of vaccines <a class="yt-timestamp" data-t="00:08:58">[00:08:58]</a>.

## Financial Risks and Rewards in Biotechnology
Investing in [[financial_risks_and_rewards_in_biotechnology_investments|biotechnology companies]] in the development phase is inherently risky and volatile, requiring a high level of knowledge to succeed due to the high rate of failed clinical trials <a class="yt-timestamp" data-t="00:04:01">[00:04:01]</a>. However, successful ventures in this field can yield substantial [[financial_risks_and_rewards_in_biotechnology_investments|financial rewards]] <a class="yt-timestamp" data-t="00:04:14">[00:04:14]</a>. Examples include:
*   **BioNTech**: Shares rose from $90 to over $350 after successful clinical trials <a class="yt-timestamp" data-t="00:04:25">[00:04:25]</a>.
*   **Moderna**: Shares increased from $70 to over $400 in less than 12 months due to its leading position in vaccine development <a class="yt-timestamp" data-t="00:04:38">[00:04:38]</a>.

## Bill Gates' Favorite Stocks for Second-Generation Vaccines

### BioNTech (BNTX)
*   **Location**: German company listed in the United States <a class="yt-timestamp" data-t="00:05:13">[00:05:13]</a>.
*   **Investment Start**: Bill Gates began investing in BioNTech at the end of 2019, six months before the crisis started <a class="yt-timestamp" data-t="00:05:22">[00:05:22]</a>.
*   **Early Success**: BioNTech, in collaboration with Pfizer, was the first company to launch an effective vaccine <a class="yt-timestamp" data-t="00:05:33">[00:05:33]</a>.
*   **Future Outlook**: The company predicts a demand of one billion doses per year from 2022 onwards, suggesting a recurrent business <a class="yt-timestamp" data-t="00:05:43">[00:05:43]</a>. Promising clinical trials could bring additional benefits <a class="yt-timestamp" data-t="00:05:55">[00:05:55]</a>.
*   **Valuation**: Estimated to earn over $37 per share, trading below 10 times earnings, which is considered attractive for a biotechnology company <a class="yt-timestamp" data-t="00:06:01">[00:06:01]</a>. If the business proves recurrent, shares could double <a class="yt-timestamp" data-t="00:06:12">[00:06:12]</a>.

### CureVac (CVAC)
*   **Location**: German company listed in the United States <a class="yt-timestamp" data-t="00:06:28">[00:06:28]</a>.
*   **Investment Start**: Bill Gates invested in CureVac in 2015 <a class="yt-timestamp" data-t="00:06:41">[00:06:41]</a>.
*   **Collaboration**: Working in collaboration with large companies, specifically GlaxoSmithKline, on second-generation vaccines <a class="yt-timestamp" data-t="00:06:52">[00:06:52]</a>.
*   **Speculative Nature**: This investment is more speculative and volatile, as CureVac is in the development phase and not yet profitable, heavily dependent on the success of its clinical trials <a class="yt-timestamp" data-t="00:07:03">[00:07:03]</a>.

### Vir Biotech (VIR)
*   **Location**: Listed in the United States <a class="yt-timestamp" data-t="00:07:37">[00:07:37]</a>.
*   **Investment Start**: Bill Gates invested in this highly innovative company in 2019 <a class="yt-timestamp" data-t="00:07:46">[00:07:46]</a>.
*   **Developments**: Developing an effective solution against multiple variants, including the Delta variant, with over 82% effectiveness <a class="yt-timestamp" data-t="00:07:52">[00:07:52]</a>.
*   **Innovative Application**: Vir Biotech is also developing a new inhaled vaccine application method, which could make participation easier for a greater percentage of the population <a class="yt-timestamp" data-t="00:08:07">[00:08:07]</a>.
*   **Speculative Nature**: Similar to CureVac, this company is in the development phase, not yet profitable, making it a highly speculative investment with high risk and potentially high reward <a class="yt-timestamp" data-t="00:08:20">[00:08:20]</a>.

These investments reflect Bill Gates' belief that [[concerns_about_future_pandemics_and_global_risks|addressing future crises]] requires advanced vaccine technology <a class="yt-timestamp" data-t="00:09:00">[00:09:00]</a>.